FDA Grants Breakthrough Device Designation to PathAI’s Dermatopathology AI Tool

PathAI has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its artificial intelligence-based dermatopathology solution, PathAssist Derm. The technology is designed to assist pathologists in evaluating digital pathology images of skin lesions and improve efficiency during the diagnostic review process.
PathAssist Derm analyses whole slide images from skin biopsies, providing AI-driven support to help pathologists prioritise cases and conduct more structured assessments.

The latest designation follows a series of regulatory milestones for PathAI. Recently, the company obtained FDA 510(k) clearance for AISight Dx, a digital pathology image management system. AISight Dx is the first FDA-cleared system of its kind to include an authorised Predetermined Change Control Plan, allowing controlled updates to AI components over time.
In addition, PathAI’s AIM-MASH AI Assist has received qualification from both the European Medicines Agency (EMA) and the FDA as the first artificial intelligence-based pathology tool designed to support drug development research.

Commenting on the breakthrough designation, PathAI CEO Dr. Andy Beck said the recognition reflects the company’s commitment to building reliable and clinically validated AI tools for pathology.
“This designation is a powerful acknowledgement of our AI capabilities and our commitment to bringing rigorously validated, clinically relevant tools to the field of digital pathology.

“By working closely with the FDA through the breakthrough devices programme, we aim to accelerate the development and review process, ensuring that this transformative technology reaches pathologists and patients as quickly as possible.”
The development of advanced diagnostic tools in dermatopathology has gained urgency due to the increasing incidence of skin cancer in the United States. Diagnosing certain skin lesions—particularly melanocytic lesions—can be challenging because of significant variability between pathologists when interpreting biopsy samples.

Research has shown that diagnostic accuracy and agreement between pathologists can fall below 50 percent for complex lesion types, highlighting the need for improved decision-support tools.
PathAssist Derm uses artificial intelligence to help pathologists evaluate cases more efficiently and prioritise their workflow, particularly as laboratories face growing diagnostic workloads.

PathAI stated that it will continue collaborating with regulatory agencies worldwide to further develop and deploy AI-driven pathology solutions aimed at enhancing diagnostic confidence and improving patient care.
Earlier, in February 2025, the company introduced the PathAssist Derm AI solution for detecting, orienting and measuring skin lesions, which operates within the AISight digital pathology image management platform.